The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (CPS ≥10) and who have not received prior chemotherapy for metastatic disease.
A confidential Trump administration budget document obtained by The Cancer Letter called for a 40% budget cut to NIH and a restructuring of the 27 existing NIH institutes and centers down to just eight. But what else is in it?
